NorthWest Biotherapeutics Inc (NWBO)

[maverick_1]

Glad to see a revival of DONOEVIL (UCLA'er Cancer Center re: Dr. Linda Liau).

I and everyone can confirm all of the following

:21 OCT 2015
NW Bio Has Entered Into An Agreement For $30 Million Of New Equity Funding From Woodford Investment Management
BETHESDA, MD, October 21, 2015 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Company has entered into agreement for funding of $30 million from Woodford Investment Management in the UK (“Woodford”).

Woodford will purchase $30 million of the Company’s common stock at $5.50 per share, for a total of 5,454,545 shares, raising Woodford’s total holdings to 25,915,937 shares, or about 28.1% of the Company. The purchase will take place in a closing on or before October 22, 2015.

NW Bio also announced that it has engaged Ondra Partners (www.ondra.com), a London-based corporate finance firm with a focus on value creation and an integrated approach to medium and long term financing and related initiatives.

In connection with this financing, the Company has issued 0.7 million shares to Cognate BioServices on the same terms as Woodford’s stock purchase, for certain current payment obligations, as well as completing the issuance of shares to Cognate that were approved and reported in November 2014, but had not yet been issued.

“NW Bio has reported encouraging interim clinical data from both its DCVax-L and DCVax-Direct clinical programs, both last spring and recently, with patient survival exceeding expectations. With this new funding from Woodford we look forward to moving these clinical programs ahead vigorously while continuing to build our organization” commented Linda Powers, CEO of NW Bio.

With the first meeting of the above in red Ondra Ptners newly minted female partner Ms. Wolfe demanding to have copies from CEO Linda Powers Patents of it's Intellectual Properties EVERYTHING WENT SOUTH: CEO Linda Powers knew that Ms. Wolfe was also consulting for Tel Aviv's VBLT with their competitive Dendritic Cell product as seen here from a 424B SEC Filing:

Our lead product candidate, VB-111, is a gene-based biologic that we are initially developing for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. We have obtained fast track designation for VB-111 in the United States for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. We have also received orphan drug designation in both the United States and Europe. Recently, we reported complete results from our Phase 2 trial of VB-111 in rGBM, demonstrating a statistically-significant benefit in overall survival and favorable response rate in patients treated with VB-111 in combination with bevacizumab. Our pivotal Phase 3 GLOBE trial of VB-111 in rGBM is ongoing under a special protocol assessment, or SPA, agreement with the U.S. Food and Drug Administration, or FDA

from:http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=10991091&RcvdDate=11/5/2015&CoName=VASCULAR%20BIOGENICS%20LTD.&FormType=424B5&View=html
The above was followed by

:Press Release
30
NOV
2015
NW Bio Plans to Expand Board, Welcomes Woodford’s Call For Independent Investigation Of Allegations In Anonymous Internet Report
BETHESDA, MD, November 30, 2015 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Board is committed to adding an additional independent director, and the Company welcomes Neil Woodford’s call for an independent investigation of allegations in a recent anonymous internet report on NW Bio. The Company’s Board is under way on both initiatives.

from: http://www.nwbio.com/nw-bio-plans-to-expand-board-welcomes-woodfords-call-for-independent-investigation-of-allegations-in-anonymous-internet-report/

ALL OF THE ABOVE WAS CAUSED BY THE late Oct 2015 RELEASE of a capsule of a 60 page NWBO report by Phase V (Anonymously written!) on SEEKING ALPHA (a site known to promote short selling articles) seen here:http://seekingalpha.com/article/3618336-northwest-biotherapeutics-house-cards-ready-collapse.

So without further favorable financing from Woodford Investments AND the SILENCE has caused the Hiroshima'ed shr price we see. Note that Woodford open market purposes and financings which cumulatively accounted for $180 mln producing an average per share cost of ~$6.80/shr l

BEFORE the above major Short Hit was the August 2014 AdamFkstein MD Anderson Dr. Budzar HIT Piece.